Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
复制标题
醋酸甲地孕酮与他莫昔芬治疗绝经后晚期乳腺癌。
DOI：
--
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
Morgan Lr
中科院分区：
文献类型：
--
作者：
Morgan Lr
106例绝经后晚期乳腺癌患者接受醋酸甲地孕酮或他莫昔芬作为主要治疗。两种药物对治疗的反应相当，未观察到任何药物的器官部位偏好。两种药物的中位缓解持续时间也相当。两种治疗均耐受良好，体重增加是观察到的最常见副作用。另一项正在进行的研究的初步结果表明，醋酸甲地孕酮与他莫昔芬在受体已被确定的对化疗敏感的乳腺癌中一样有效。
One hundred six postmenopausal patients with advanced breast cancer received megestrol acetate or tamoxifen as primary therapy. Response to therapy was comparable for the two agents, with no organ site preference observed for either agent. The median duration of remission was also comparable for the two agents. Both treatments were well tolerated, with weight gain being the most common side effect observed. Initial results of another ongoing study suggest that megestrol acetate is as effective as tamoxifen in hormone-sensitive breast cancer in which receptors have been identified.